what would you tell week-1 you about compounding
I have had 17 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 20 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 96.8% against a claimed 97.2%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
What is the actual shortage list status right now?
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
What is the actual shortage list status right now?
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Crossposting this to c/maintenancephase because the people who need it are not reading this community.
no pharmacy referral codes, naming is fine, recruiting is not
503B compounding is different from 503A, different rules, different legality
Yeah, 503A and 503B are different regulatory animals.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
telehealth prescriber models exist, pricing differs by state
This is correct. The shortage list does expire and the rules change.
Respectfully this is a sample of one presented as a finding.
the shortage list is temporary, it ends and compounding becomes illegal again
the shortage list is temporary, it ends and compounding becomes illegal again
Disagree on that part. 98.7% and 98.9% on the same vial is normal.
Yeah, 503A and 503B are different regulatory animals.
the the UK situation is different from the US, different regulations
Strongly agree. API source transparency matters.
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
no pharmacy referral codes, naming is fine, recruiting is not
Strongly agree. API source transparency matters.
the 503A/503B distinction is load-bearing, do not blur it
the 503A/503B distinction is load-bearing, do not blur it
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
telehealth prescriber models exist, pricing differs by state
I am going to push back on this slightly.
API transparency is the question that separates good compounders from sketchy ones
the 503A/503B distinction is load-bearing, do not blur it
the 503A/503B distinction is load-bearing, do not blur it
You have restated the marketing copy. What is the actual substance here.
- 1Strongly agree. API source transparency matters.6 comments in this branch · started by u/step_count_stan
- 2Crossposting this to c/maintenancephase because the people who need it are…5 comments in this branch · started by u/honest_syringe_2025